Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Gallbladder Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 11Cisplatin 10pembrolizumab 7Fluorouracil 3Drug Therapy 3spartalizumab 2derazantinib 2Leucovorin 2trametinib 1tislelizumab 1silmitasertib 1seribantumab 1pertuzumab 1olutasidenib 1galactomannan 1exatecan 1durvalumab 1becatecarin 1Tegafur 1Standard of Care 1S 1 (combination) 1Ritonavir 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Observation 1Nivolumab 1Molecular Diagnostic Techniques 1Microscopy, Confocal 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bile Duct Neoplasms × becatecarin × Clear all
NCT00090025 2009-01-14

XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors

Helsinn Healthcare SA

Phase 3 Terminated
248 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡